A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523230-77-00

Enrollment

Registered

2026-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

Brief summary

Best Overall Response Rate (BORR) as defined by the BCC-RECIST-like criteria according to an Independent Central Review (ICR).

Interventions

DRUGFibromun

DRUGDarleukin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Best Overall Response Rate (BORR) as defined by the BCC-RECIST-like criteria according to an Independent Central Review (ICR).	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 12, 2026